Comparison
A comparison of two peptides commonly discussed for gut, inflammation, and tissue-repair claims.
KPV is more mechanism-heavy; BPC-157 carries stronger regulatory and product-quality warnings. The useful comparison is what each claim actually rests on.
KPV evidence is dominated by cell and animal work. BPC-157 has a small human record, but not enough to establish a dependable gut or injury protocol. Neither has strong human evidence for the broad repair claims attached to it online.
Neither is an FDA-approved treatment for gut inflammation or tissue repair. Route and product form still matter: a topical or oral experiment does not establish an injectable regimen, and a compounded or research-market vial does not inherit another product's evidence.
Yes. Online protocols often turn a study amount or animal experiment into a consumer cycle without preserving the original route, formulation, population, or monitoring. The page-level source tables show where those jumps occur.
| Dimension | KPV | BPC-157 |
|---|---|---|
| Overall evidence grade | D | D |
| Evidence label | Mostly preclinical | Limited human evidence |
| Regulatory status | Investigational / not approved | Not FDA-approved for listed uses |
| Editorial confidence | Low confidence | Low confidence |
| Efficacy | 1/5 limited | 1/5 limited |
| Safety | 1/5 limited | 1/5 limited |
| Regulatory risk | 4/5 high | 4/5 high |
| Product quality risk | 4/5 high | 4/5 high |
| Primary claim categories | Inflammation claims, Gut health claims, Skin barrier claims | Injury recovery, Tendon and ligament claims, Gut and inflammation claims |
KPV is mostly a preclinical topic. The literature explains why gut, skin, wound, and antimicrobial claims exist, but it does not provide a human treatment protocol.
BPC-157 has limited human evidence. The most useful sources are an oral trial registry, small human reports, review context, and FDA compounding concerns; the recovery protocol culture is much louder than the human data.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.